Compare Eni SpA (E) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Novartis AG — how do they compare? Eni SpA trades at $56.1 (market cap $79.81B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3.4× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Novartis AG for 82 Days on average.
| E | NVS | |
|---|---|---|
Market Cap | $79.81B | $268.57B |
Volume | 365,912 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $57.61 | $168.62 |
52-Week Low | $34.03 | $121.80 |
Typical Hold Time | 53 Days | 82 Days |
Enterprise Value | $104.34B | $309.89B |
Dividend Yield | 4.39% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $53.96, down 1.08% on the day, amid a bearish technical signal and mixed earnings performance. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97%. Recent news highlights strategic moves in humanoid robotics, LNG projects, and fuel discounts. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85, while cash flow remains positive but net cash flow turned negative in 2026 projections.
The outlook is cautious; low valuations and dividend payments offer value, but revenue declines and earnings misses pose risks. Analyst consensus is mixed with 34.62% buy ratings. Key risks include energy price volatility and execution of new tech initiatives. Further upside depends on stabilizing revenue and meeting earnings expectations.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
